EMA issues warning of IVF drug shortage due to manufacturing issues
The European Medicines Agency recently noted the shortage of a drug that is used frequently in IVF procedures where women have ovarian stimulation (i.e. fertility treatment where the ovaries are stimulated to produce more eggs).
The drug, known as cetrotide, is now facing a shortage in Europe due to a potential manufacturing issue.
The EMA’s warning on Wednesday states that a technical issue at the main manufacturing site for cetrotide resulted in the closure of the site between December 2021 and March of this year. This led to reductions and delays in the supply of cetrotide.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.